Researchers at Stony Brook University have reported a new therapeutic strategy that appears to dramatically shrink tumors in a laboratory model of non‑small cell lung cancer (NSCLC), a disease that remains one of the top causes of cancer death in the United States.
Multi‑targeted miRNA therapy shows strong tumor reduction
The study was published in Molecular Therapy.
The work was led by Jingfang Ju, a professor of pathology at the Renaissance School of Medicine and director of the Oncogenic Drivers and Mechanisms of Carcinogenesis program at the Stony Brook Cancer Center. Ju’s team engineered a compound that links the naturally occurring microRNA‑129 (miR‑129) with the chemotherapy drug gemcitabine, creating a single molecule they call Gem‑miR‑129.
MiR‑129 is a non‑coding RNA that normally acts as a tumor suppressor, regulating gene activity that can drive cancer growth. By attaching gemcitabine, the researchers aimed to improve the stability and delivery of the miRNA while adding the cytotoxic effect of the chemotherapy. In mouse models, the combined agent entered cancer cells without an external carrier and simultaneously inhibited three oncogenic drivers—HMGB1, YAP1 and PBX3.
Related: New Alzheimer’s drug safety questioned
“The results in the model were remarkable, with the impact of tumor shrinkage reaching more than 95%,” Ju said. The treated mice also lived several weeks longer than control groups, a gain the investigators estimate could correspond to roughly five to fifteen additional years of human life if the effect translates to patients.
Potential to overcome resistance to existing therapies
Current first‑line treatment for many NSCLC patients includes gemcitabine, while a subset with EGFR mutations receives tyrosine kinase inhibitors (TKIs). Although TKIs can initially produce strong responses, about half of those cancers eventually develop resistance, limiting long‑term benefit.
Gem‑miR‑129 is designed specifically for tumors that have become resistant to TKIs. By suppressing multiple oncogenes linked to both intrinsic and acquired resistance, the compound aims to keep the cancer vulnerable to both chemotherapy and EGFR‑targeted drugs.
Ju explained that once the gemcitabine portion of the molecule is released, it can act at low doses to inhibit tumor‑infiltrating regulatory T cells (Ti‑Tregs). Those cells normally dampen the activity of cytotoxic CD4 and CD8 T cells. Reducing Ti‑Tregs may allow the immune system to attack the tumor more effectively, adding an immunologic dimension to the direct anti‑cancer action.
“Resistance is the primary reason why current lung cancer therapies stop working for cancer patients, and for that reason, this approach is highly promising,” the professor emphasized.
Related: Wildfire smoke affects New York bird sightings
In the animal study, the investigators observed no obvious toxic side effects, a finding that supports the feasibility of moving the candidate forward into human testing.
From a broader perspective, this approach mirrors earlier efforts where combining a biologic agent with a standard chemotherapy aimed to tackle resistance mechanisms. Past trials with dual‑targeted strategies have yielded mixed results, often limited by delivery challenges or unexpected toxicity. The ability of Gem‑miR‑129 to enter cells without a carrier and to act on several pathways at once could address some of those historical hurdles, though clinical validation will be necessary.
Next steps toward clinical evaluation
The research team plans to file an Investigational New Drug (IND) application, a regulatory step that will assess safety before any human trials begin. Funding for the work came partially from a Veterans Affairs Merit Award and from a Stony Brook Cancer Center pilot grant.
If the IND is approved, the investigators hope to enroll patients whose NSCLC has progressed despite TKI therapy. Successful translation could add a new option for a disease where treatment options remain limited for many sufferers.